Who Paid My Doc
Myron Levin
Pediatric Infectious Diseases Aurora, CO Medical Doctor
NPI 1306920038 CMS profile 331123
12605 E 16Th Ave, Aurora, CO 80045
General payments
$291,777
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$4,490,206
Through program year 2025, Myron Levin of Aurora, CO is reported in the CMS Open Payments database as having received $291,777 across 213 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,490,206 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $46,622 | 12 | |
| 2024 | General | $28,593 | 21 | |
| 2023 | General | $53,408 | 42 | |
| 2022 | General | $50,676 | 38 | |
| 2021 | General | $40,322 | 23 | |
| 2020 | General | $39,212 | 16 | |
| 2019 | General | $32,944 | 61 |
Beside peers
- Myron Levin
- Pediatric Infectious Diseases median
- Middle half of Pediatric Infectious Diseases
- National median
In program year 2025, general payments to Myron Levin were reported at $46,622. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.
Show as a table
| Year | Myron Levin | Pediatric Infectious Diseases median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $32,944 | $175 | $34–$2,175 | $163 |
| 2020 | $39,212 | $521 | $34–$6,009 | $114 |
| 2021 | $40,322 | $1,077 | $39–$4,557 | $132 |
| 2022 | $50,676 | $232 | $53–$6,196 | $149 |
| 2023 | $53,408 | $140 | $52–$4,662 | $160 |
| 2024 | $28,593 | $198 | $52–$3,860 | $164 |
| 2025 | $46,622 | $126 | $41–$2,094 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
213 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Infectious Diseases in Colorado
Eric Simoes
Pediatric Infectious Diseases · Aurora, CO
Edwin Asturias
Pediatric Infectious Diseases · Aurora, CO
Samuel Dominguez
Pediatric Infectious Diseases · Aurora, CO
Daniel Olson
Pediatric Infectious Diseases · Aurora, CO
Mary Glode
Pediatric Infectious Diseases · Aurora, CO
Bazak Sharon
Pediatric Infectious Diseases · Centennial, CO
Related records
Pediatric Infectious Diseases in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Infectious Diseases
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.